Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.

about

Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.

Item

http://www.wikidata.org/entity/Q39022303

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Management of adverse events i ...... nhibitors in multiple myeloma.

@en

Management of adverse events i ...... nhibitors in multiple myeloma.

@nl

type

Item

label

Management of adverse events i ...... nhibitors in multiple myeloma.

@en

Management of adverse events i ...... nhibitors in multiple myeloma.

@nl

prefLabel

Management of adverse events i ...... nhibitors in multiple myeloma.

@en

Management of adverse events i ...... nhibitors in multiple myeloma.

@nl

P1476

Management of adverse events i ...... nhibitors in multiple myeloma.

@en

P2093

Alessandra Larocca

http://www.w3.org/2001/XMLSchema#string

Francesca Bonello

http://www.w3.org/2001/XMLSchema#string

Marco Salvini

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

P2860

From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

P304

75-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1266264

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27894203

http://www.w3.org/2001/XMLSchema#string